https://medicaldialogues.in/news/industry/pharma/janssen-seeks-usfda-nod-for-niraparib-and-abiraterone-acetate-dual-action-tablet-plus-prednisone-to-treat-patients-with-metastatic-castration-resistant-prostate-cancerwith-brca-gene-mutations-107872